Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk to cut insulin prices in the U.S.

Danish drugmaker Novo Nordisk will offer cheaper insulin to U.S. diabetics in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

Read More »

U.S. group says Novartis MS drug price out of line with benefit

A U.S. group that reviews the value of medicines issued a critical report on Novartis’ Mayzent, calling the new multiple sclerosis drug’s $88,561 list price “far out of line” compared with the product’s benefits for patients.

Read More »

Two drugmakers to pay in U.S. charity kickback probe

Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.

Read More »

Senate Finance Committee and House Oversight Committee Take Aim at Drug Pricing

The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.

Read More »

EVERSANA unveils Health Strategies Insights

EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.

Read More »

Walgreens settles U.S. civil fraud lawsuits

Walgreens Boots Alliance Inc. will pay $269.2 million to settle two whistleblower lawsuits accusing the pharmacy chain of civil fraud for overbilling federal healthcare programs for over a decade.

Read More »

U.S. insulin costs per patient nearly doubled from 2012 to 2016: study

The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.

Read More »

J&J raises U.S. prices on around two dozen drugs

Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.

Read More »

7 Biotech Trends to Look Out for in 2019

Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.

Read More »

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

Biogen Inc.’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom